Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A Return on Equity

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A (FBIOP) currently reports a ROE of 64.01%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's ROE history and peer comparisons.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's ROE of 64.01% is higher than the Healthcare sector average of 22.01%. That is roughly 190.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's current 64.01% should be judged against Healthcare norms (sector average: 22.01%) and against FBIOP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 64.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A, and consider following FBIOP for alerts when major investors trade the stock.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A is classified in the Healthcare sector. On ROE, it currently shows 64.01% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FBIOP with unrelated industries.